1-13 of 13
Geoffrey I. Shapiro
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma

James M. Cleary, Srivatsan Raghavan, Qibiao Wu, Yvonne Y. Li, Liam F. Spurr, Hersh V. Gupta, Douglas A. Rubinson, Isobel J. Fetter, Jason L. Hornick, Jonathan A. Nowak, Giulia Siravegna, Lipika Goyal, Lei Shi, Lauren K. Brais, Maureen Loftus, Atul B. Shinagare, Thomas A. Abrams, Thomas E. Clancy, Jiping Wang, Anuj K. Patel, Franck Brichory, Anne Vaslin Chessex, Ryan J. Sullivan, Rachel B. Keller, Sarah Denning, Emma R. Hill, Geoffrey I. Shapiro, Anna Pokorska-Bocci, Claudio Zanna, Kimmie Ng, Deborah Schrag, Pasi A. Jänne, William C. Hahn, Andrew D. Cherniack, Ryan B. Corcoran, Matthew Meyerson, Antoine Daina, Vincent Zoete, Nabeel Bardeesy, Brian M. Wolpin
Journal: Cancer Discovery
Cancer Discov (2021) 11 (10): 2488–2505.
https://doi.org/10.1158/2159-8290.CD-20-1669
Published: 01 October 2021
View article titled, <em>FGFR2</em> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
Open the PDF for <em>FGFR2</em> Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma in another window
Includes: Supplementary data
Journal Articles

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Lillian M. Smyth, Sarina A. Piha-Paul, Helen H. Won, Alison M. Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I. Shapiro, Dejan Juric, Ingrid A. Mayer, Carlos L. Arteaga, Macarena I. de la Fuente, Adam M. Brufksy, Iben Spanggaard, Morten Mau-Sørensen, Monica Arnedos, Victor Moreno, Valentina Boni, Joohyuk Sohn, Lee S. Schwartzberg, Xavier Gonzàlez-Farré, Andrés Cervantes, François-Clement Bidard, Alexander N. Gorelick, Richard B. Lanman, Rebecca J. Nagy, Gary A. Ulaner, Sarat Chandarlapaty, Komal Jhaveri, Elena I. Gavrila, Catherine Zimel, S. Duygu Selcuklu, Myra Melcer, Aliaksandra Samoila, Yanyan Cai, Maurizio Scaltriti, Grace Mann, Feng Xu, Lisa D. Eli, Melanie Dujka, Alshad S. Lalani, Richard Bryce, José Baselga, Barry S. Taylor, David B. Solit, Funda Meric-Bernstam, David M. Hyman
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (2): 198–213.
https://doi.org/10.1158/2159-8290.CD-19-0966
Published: 05 February 2020
View article titled, Efficacy and Determinants of Response to HER Kinase Inhibition in <em>HER2</em>-Mutant Metastatic Breast Cancer
Open the PDF for Efficacy and Determinants of Response to HER Kinase Inhibition in <em>HER2</em>-Mutant Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer

Constantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, Anita K. Mehta, Aditi Kothari, Dan Wang, Tanvi Visal, Michelle K. Li, Jocelin Pinto, Jessica A. Castrillon, Emily M. Cheney, Peter Bouwman, Jos Jonkers, Sven Rottenberg, Jennifer L. Guerriero, Gerburg M. Wulf, Geoffrey I. Shapiro
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2019) 9 (6): 722–737.
https://doi.org/10.1158/2159-8290.CD-18-1218
Published: 03 June 2019
View article titled, PARP Inhibitor Efficacy Depends on CD8<sup>+</sup> T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
Open the PDF for PARP Inhibitor Efficacy Depends on CD8<sup>+</sup> T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids

Sarah J. Hill, Brennan Decker, Emma A. Roberts, Neil S. Horowitz, Michael G. Muto, Michael J. Worley, Jr, Colleen M. Feltmate, Marisa R. Nucci, Elizabeth M. Swisher, Huy Nguyen, Chunyu Yang, Ryuji Morizane, Bose S. Kochupurakkal, Khanh T. Do, Panagiotis A. Konstantinopoulos, Joyce F. Liu, Joseph V. Bonventre, Ursula A. Matulonis, Geoffrey I. Shapiro, Ross S. Berkowitz, Christopher P. Crum, Alan D. D'Andrea
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (11): 1404–1421.
https://doi.org/10.1158/2159-8290.CD-18-0474
Published: 01 November 2018
View article titled, Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Open the PDF for Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids in another window
Includes: Supplementary data
Journal Articles

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

Andrew J. Aguirre, Jonathan A. Nowak, Nicholas D. Camarda, Richard A. Moffitt, Arezou A. Ghazani, Mehlika Hazar-Rethinam, Srivatsan Raghavan, Jaegil Kim, Lauren K. Brais, Dorisanne Ragon, Marisa W. Welch, Emma Reilly, Devin McCabe, Lori Marini, Kristin Anderka, Karla Helvie, Nelly Oliver, Ana Babic, Annacarolina Da Silva, Brandon Nadres, Emily E. Van Seventer, Heather A. Shahzade, Joseph P. St. Pierre, Kelly P. Burke, Thomas Clancy, James M. Cleary, Leona A. Doyle, Kunal Jajoo, Nadine J. McCleary, Jeffrey A. Meyerhardt, Janet E. Murphy, Kimmie Ng, Anuj K. Patel, Kimberly Perez, Michael H. Rosenthal, Douglas A. Rubinson, Marvin Ryou, Geoffrey I. Shapiro, Ewa Sicinska, Stuart G. Silverman, Rebecca J. Nagy, Richard B. Lanman, Deborah Knoerzer, Dean J. Welsch, Matthew B. Yurgelun, Charles S. Fuchs, Levi A. Garraway, Gad Getz, Jason L. Hornick, Bruce E. Johnson, Matthew H. Kulke, Robert J. Mayer, Jeffrey W. Miller, Paul B. Shyn, David A. Tuveson, Nikhil Wagle, Jen Jen Yeh, William C. Hahn, Ryan B. Corcoran, Scott L. Carter, Brian M. Wolpin
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (9): 1096–1111.
https://doi.org/10.1158/2159-8290.CD-18-0275
Published: 04 September 2018
View article titled, Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Open the PDF for Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine in another window
Includes: Supplementary data
Journal Articles

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation

Jiehui Deng, Eric S. Wang, Russell W. Jenkins, Shuai Li, Ruben Dries, Kathleen Yates, Sandeep Chhabra, Wei Huang, Hongye Liu, Amir R. Aref, Elena Ivanova, Cloud P. Paweletz, Michaela Bowden, Chensheng W. Zhou, Grit S. Herter-Sprie, Jessica A. Sorrentino, John E. Bisi, Patrick H. Lizotte, Ashley A. Merlino, Max M. Quinn, Lauren E. Bufe, Annan Yang, Yanxi Zhang, Hua Zhang, Peng Gao, Ting Chen, Megan E. Cavanaugh, Amanda J. Rode, Eric Haines, Patrick J. Roberts, Jay C. Strum, William G. Richards, Jochen H. Lorch, Sareh Parangi, Viswanath Gunda, Genevieve M. Boland, Raphael Bueno, Sangeetha Palakurthi, Gordon J. Freeman, Jerome Ritz, W. Nicholas Haining, Norman E. Sharpless, Haribabu Arthanari, Geoffrey I. Shapiro, David A. Barbie, Nathanael S. Gray, Kwok-Kin Wong
Journal: Cancer Discovery
Cancer Discov (2018) 8 (2): 216–233.
https://doi.org/10.1158/2159-8290.CD-17-0915
Published: 04 February 2018
View article titled, CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Open the PDF for CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation in another window
Includes: Supplementary data
Journal Articles

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Ryan J. Sullivan, Jeffrey R. Infante, Filip Janku, Deborah Jean Lee Wong, Jeffrey A. Sosman, Vicki Keedy, Manish R. Patel, Geoffrey I. Shapiro, James W. Mier, Anthony W. Tolcher, Andrea Wang-Gillam, Mario Sznol, Keith Flaherty, Elizabeth Buchbinder, Richard D. Carvajal, Anna M. Varghese, Mario E. Lacouture, Antoni Ribas, Sapna P. Patel, Gary A. DeCrescenzo, Caroline M. Emery, Anna L. Groover, Saurabh Saha, Mary Varterasian, Dean J. Welsch, David M. Hyman, Bob T. Li
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (2): 184–195.
https://doi.org/10.1158/2159-8290.CD-17-1119
Published: 04 February 2018
View article titled, First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Open the PDF for First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Amita Patnaik, Lee S. Rosen, Sara M. Tolaney, Anthony W. Tolcher, Jonathan W. Goldman, Leena Gandhi, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew W. Rasco, John F. Hilton, Aejaz Nasir, Richard P. Beckmann, Andrew E. Schade, Angie D. Fulford, Tuan S. Nguyen, Ricardo Martinez, Palaniappan Kulanthaivel, Lily Q. Li, Martin Frenzel, Damien M. Cronier, Edward M. Chan, Keith T. Flaherty, Patrick Y. Wen, Geoffrey I. Shapiro
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2016) 6 (7): 740–753.
https://doi.org/10.1158/2159-8290.CD-16-0095
Published: 30 June 2016
View article titled, Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors
Open the PDF for Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Targeting CDK4 and CDK6: From Discovery to Therapy

Charles J. Sherr, David Beach, Geoffrey I. Shapiro
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2016) 6 (4): 353–367.
https://doi.org/10.1158/2159-8290.CD-15-0894
Published: 03 April 2016
View article titled, Targeting CDK4 and CDK6: From Discovery to Therapy
Open the PDF for Targeting CDK4 and CDK6: From Discovery to Therapy in another window
Journal Articles

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Panagiotis A. Konstantinopoulos, Raphael Ceccaldi, Geoffrey I. Shapiro, Alan D. D'Andrea
Journal: Cancer Discovery
Cancer Discov (2015) 5 (11): 1137–1154.
https://doi.org/10.1158/2159-8290.CD-15-0714
Published: 01 November 2015
View article titled, Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Open the PDF for Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer in another window
Journal Articles

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

Nikhil Wagle, Brian C. Grabiner, Eliezer M. Van Allen, Eran Hodis, Susanna Jacobus, Jeffrey G. Supko, Michelle Stewart, Toni K. Choueiri, Leena Gandhi, James M. Cleary, Aymen A. Elfiky, Mary Ellen Taplin, Edward C. Stack, Sabina Signoretti, Massimo Loda, Geoffrey I. Shapiro, David M. Sabatini, Eric S. Lander, Stacey B. Gabriel, Philip W. Kantoff, Levi A. Garraway, Jonathan E. Rosenberg
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2014) 4 (5): 546–553.
https://doi.org/10.1158/2159-8290.CD-13-0353
Published: 01 May 2014
View article titled, Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib
Open the PDF for Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib in another window
Includes: Supplementary data
Journal Articles

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Esra A. Akbay, Shohei Koyama, Julian Carretero, Abigail Altabef, Jeremy H. Tchaicha, Camilla L. Christensen, Oliver R. Mikse, Andrew D. Cherniack, Ellen M. Beauchamp, Trevor J. Pugh, Matthew D. Wilkerson, Peter E. Fecci, Mohit Butaney, Jacob B. Reibel, Margaret Soucheray, Travis J. Cohoon, Pasi A. Janne, Matthew Meyerson, D. Neil Hayes, Geoffrey I. Shapiro, Takeshi Shimamura, Lynette M. Sholl, Scott J. Rodig, Gordon J. Freeman, Peter S. Hammerman, Glenn Dranoff, Kwok-Kin Wong
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2013) 3 (12): 1355–1363.
https://doi.org/10.1158/2159-8290.CD-13-0310
Published: 10 December 2013
View article titled, Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Open the PDF for Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Josep Tabernero, Geoffrey I. Shapiro, Patricia M. LoRusso, Andres Cervantes, Gary K. Schwartz, Glen J. Weiss, Luis Paz-Ares, Daniel C. Cho, Jeffrey R. Infante, Maria Alsina, Mrinal M. Gounder, Rick Falzone, Jamie Harrop, Amy C. Seila White, Iva Toudjarska, David Bumcrot, Rachel E. Meyers, Gregory Hinkle, Nenad Svrzikapa, Renta M. Hutabarat, Valerie A. Clausen, Jeffrey Cehelsky, Saraswathy V. Nochur, Christina Gamba-Vitalo, Akshay K. Vaishnaw, Dinah W.Y. Sah, Jared A. Gollob, Howard A. Burris, III
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2013) 3 (4): 406–417.
https://doi.org/10.1158/2159-8290.CD-12-0429
Published: 10 April 2013
View article titled, First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement
Open the PDF for First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement in another window
Includes: Supplementary data